BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary
BioSyent Pharma Inc. has received marketing approval from Health Canada for its
unique new oral iron supplement FeraMAX(R) Powder.


FeraMAX(R) Powder joins fast growing FeraMAX(R) 150 (first six months 2012 sales
up 116% over same period 2011) in providing healthcare professionals and their
patients with a safe, effective and well tolerated oral iron supplement.
FeraMAX(R) Powder is indicated for the prevention of iron deficiency and iron
deficiency anaemia in newborns, infants, children and adults.


FeraMAX(R) Powder is the only oral iron product available in a dissolvable
powder and comes in pleasant tasting grape/raspberry flavoured gluten and
alcohol-free crystals which can be conveniently dosed by diluting in water or
mixing with soft foods. This innovative new product is based upon the same
doctor recommended, proprietary, non-ionic polysaccharide-iron complex
technology found in FeraMAX(R) 150. 


Other oral iron products intended for infants and children either have an
unpleasant heavy metallic taste which deter patient compliance or they come in
formulations containing alcohol which healthcare professionals and caregivers
prefer to avoid. In addition to its clear advantages in the pediatric market,
FeraMAX(R) Powder is also well suited for adult patients that have difficulty
swallowing pills.


FeraMAX(R) Powder is the first innovation in the pediatric oral iron market in
Canada in almost 50 years. The Canadian market launch will be the global
introduction of this new product and provides BioSyent Pharma with a unique
offering for international marketing partners.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada. The
Company is focused on medications that occupy a niche in the market, that are
unique either due to complexity of manufacture or provide novel technological or
therapeutic advantages, or that are backed by strong partners holding
intellectual property rights that are defendable. This strategy allows the
Company to market these medications as brands owned by, or licensed to, it.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.
Biosyent (TSXV:RX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Biosyent Charts.
Biosyent (TSXV:RX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Biosyent Charts.